Diabetic Gastroparesis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Diabetic Gastroparesis Epidemiology Forecast Report Coverage

Expert Market Research's “Diabetic Gastroparesis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of diabetic gastroparesis. It projects the future incidence and prevalence rates of diabetic gastroparesis cases across various populations. The study covers age, gender, and type as major determinants of the diabetic gastroparesis population. The report highlights patterns in the prevalence of diabetic gastroparesis over time and projects future trends based on multiple variables.

Diabetic Gastroparesis Understanding: Disease Overview

Diabetic gastroparesis is a chronic complication of diabetes characterized by delayed gastric emptying without mechanical obstruction. Symptoms include nausea, vomiting, early satiety, bloating, and abdominal discomfort. It results from autonomic neuropathy affecting gastric motility, commonly in patients with long-standing type 1 or type 2 diabetes. The disorder significantly impacts nutrition, glycemic control, and quality of life, leading to increased hospitalizations and healthcare utilization. Risk factors include poor glycemic control, long disease duration, and comorbidities such as neuropathy and cardiovascular disease.

Diabetic Gastroparesis Epidemiology Perspective

The diabetic gastroparesis epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the diabetic gastroparesis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for diabetic gastroparesis and their trends. The diabetic gastroparesis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Diabetic gastroparesis affects approximately 9.3% of individuals with diabetes worldwide, indicating a significant burden among the global diabetic population.
• Prevalence is higher in women (4.6%) compared with men (3.4%), reflecting a consistent sex-related trend in global pooled data.
• Among people with diabetes globally, type 2 diabetes patients show higher prevalence (12.5%) than type 1 diabetes patients (8.3%).
• Diabetic gastroparesis is more common in diabetic adults under 60 years (15.8%) than in those 60 years and older (5.5%), indicating age-associated variation.

Read more about this report - Request a Free Sample

Country-wise Diabetic Gastroparesis Epidemiology Segment

The diabetic gastroparesis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, Diabetic gastroparesis represents the predominant etiology within the broader gastroparesis population. A large U.S. population-based analysis reported an overall standardized gastroparesis prevalence of 267.7 per 100,000 adults. Notably, 57.4% of all identified gastroparesis cases were attributed to diabetes, including 5.7% linked to type 1 diabetes and 51.7% to type 2 diabetes. Moreover, a population-based UK study using national primary care records reported that the overall prevalence of diagnosed gastroparesis was 13.8 per 100,000 persons in 2016. Diabetes was one of the leading causes, accounting for 37.5% of gastroparesis cases, highlighting the major contribution of diabetic gastroparesis in the UK. These findings underscore the substantial contribution of diabetes to gastroparesis burden worldwide and highlight its clinical and epidemiological significance.

Diabetic Gastroparesis: Treatment Overview

Management includes dietary modifications, prokinetic agents like metoclopramide or erythromycin, antiemetics, and glycemic optimization. In refractory cases, gastric electrical stimulation or enteral feeding may be considered. Emerging therapies include novel ghrelin agonists and motilin receptor modulators, are currently under clinical evaluation. Multidisciplinary approaches involving endocrinologists, gastroenterologists, and dietitians are critical to improving symptom control, nutritional status, and overall quality of life. Patient education, lifestyle management, and continuous monitoring remain key components of effective treatment strategies.

Key Questions Answered

• What are the key findings of diabetic gastroparesis epidemiology in the 8 major markets?
• What will be the total number of patients with diabetic gastroparesis across the 8 major markets during the forecast period?
• What was the country-wise diabetic gastroparesis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of diabetic gastroparesis during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of diabetic gastroparesis during the forecast period of 2026-2035?
• What are the currently available treatments for diabetic gastroparesis?
• What are the disease risks, signs, symptoms, and unmet needs of diabetic gastroparesis?

Scope of the Diabetic Gastroparesis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of diabetic gastroparesis based on several factors.
• Diabetic Gastroparesis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The diabetic gastroparesis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Diabetic Gastroparesis Treatment Market

Diabetic Gastroparesis Drug Pipeline Analysis